Literature DB >> 23558065

Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges.

Jia Xiao1, Rui Guo, Man Lung Fung, Emily C Liong, George L Tipoe.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver injury and mortality in Western countries and China. However, as to date, there is no direct and effective therapy for this disease. The aim of this review is to analyze the key progress and challenges of main current therapeutic approaches in NAFLD. DATA SOURCE: We carried out a PubMed search of English-language articles relevant to NAFLD therapy.
RESULTS: There are two major therapeutic strategies for NAFLD treatment: (1) lifestyle interventions (including weight reduction, dietary modification and physical exercise) and (2) pharmaceutical therapies. Lifestyle interventions, particularly chronic and moderate intensity exercise, are the most effective and recognized clinical therapies for NAFLD. For pharmaceutical therapies, although their effects and mechanisms have been extensively investigated in laboratory studies, they still need further tests and investigations in clinical human trials.
CONCLUSION: Future advancement of NAFLD therapy should focus on the mechanistic studies on cell based and animal models and human clinical trials of exercise, as well as the combination of lifestyle intervention and pharmaceutical therapy specifically targeting main signaling pathways related to lipid metabolism, oxidative stress and inflammation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23558065     DOI: 10.1016/s1499-3872(13)60021-1

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  14 in total

1.  Bee's honey attenuates non-alcoholic steatohepatitis-induced hepatic injury through the regulation of thioredoxin-interacting protein-NLRP3 inflammasome pathway.

Authors:  Jia Xiao; Yingxia Liu; Feiyue Xing; Tung Ming Leung; Emily C Liong; George L Tipoe
Journal:  Eur J Nutr       Date:  2015-07-02       Impact factor: 5.614

Review 2.  Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Ciarán P Fisher; Andrzej M Kierzek; Nick J Plant; J Bernadette Moore
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 3.  Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease.

Authors:  Hye-Jin Yoon; Bong Soo Cha
Journal:  World J Hepatol       Date:  2014-11-27

Review 4.  The Role of Phytosterols in Nonalcoholic Fatty Liver Disease.

Authors:  Otilia Frasinariu; Roxana Serban; Laura Mihaela Trandafir; Ingrith Miron; Magdalena Starcea; Ioana Vasiliu; Anna Alisi; Oana Raluca Temneanu
Journal:  Nutrients       Date:  2022-05-24       Impact factor: 6.706

5.  Activation of the CXCL16/CXCR6 pathway promotes lipid deposition in fatty livers of apolipoprotein E knockout mice and HepG2 cells.

Authors:  Kun Ling Ma; Yu Wu; Yang Zhang; Gui Hua Wang; Ze Bo Hu; Xiong Zhong Ruan
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

Review 6.  Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications.

Authors:  Federica Del Chierico; Daniela Gnani; Pamela Vernocchi; Andrea Petrucca; Anna Alisi; Bruno Dallapiccola; Valerio Nobili; Putignani Lorenza
Journal:  Int J Mol Sci       Date:  2014-01-07       Impact factor: 5.923

7.  Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease.

Authors:  Aida A Korish; Maha M Arafah
Journal:  BMC Complement Altern Med       Date:  2013-10-13       Impact factor: 3.659

8.  Reduced oxidative stress contributes to the lipid lowering effects of isoquercitrin in free fatty acids induced hepatocytes.

Authors:  Waseem Hassan; Gao Rongyin; Abdelkader Daoud; Lin Ding; Lulu Wang; Jun Liu; Jing Shang
Journal:  Oxid Med Cell Longev       Date:  2014-10-22       Impact factor: 6.543

9.  Radix Hedysari polysaccharide suppresses lipid metabolism dysfunction in a rat model of non‑alcoholic fatty liver disease via adenosine monophosphate‑activated protein kinase pathway activation.

Authors:  Wei-Ming Sun; Yu-Ping Wang; Yong-Qiang Duan; Hong-Xia Shang; Wei-Dong Cheng
Journal:  Mol Med Rep       Date:  2014-06-13       Impact factor: 2.952

10.  Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model.

Authors:  Jia Xiao; Feiyue Xing; Jie Huo; Man Lung Fung; Emily C Liong; Yick Pang Ching; Aimin Xu; Raymond Chuen Chung Chang; Kwok Fai So; George L Tipoe
Journal:  Sci Rep       Date:  2014-07-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.